Celltrion Acquires Swiss Pharmaceutical Distributor to Secure Local Distribution Network and Workforce
Daegum, Approximately 30 Billion KRW in Scale
Celltrion has acquired the Swiss pharmaceutical distributor 'Icon'.
Incheon Songdo Celltrion Plant 2 Overview. / Incheon - Photo by Hyunmin Kim kimhyun81@
View original imageOn the 15th, Celltrion announced that the acquisition of Icon was completed this month, with the acquisition cost amounting to approximately 30 billion KRW.
The acquisition was made through Celltrion's Hungarian subsidiary, incorporating Icon as a subsidiary. Celltrion explained that this structure was chosen considering operational efficiency and marketing synergy.
Through this acquisition, Celltrion will secure distribution networks and professional personnel established locally in Switzerland.
Switzerland has formed a relatively large pharmaceutical market compared to its population size and is evaluated to have high potential for sales expansion due to high drug prices.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- NVIDIA Reports $81.6 Billion in Q1 Revenue, Surpassing Expectations
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Yoo Min-hyuk, head of Celltrion's European Business Division, said, "This acquisition of Icon is meaningful in that we pursued European business expansion by acquiring a competitive local company."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.